{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T20:03:11Z","timestamp":1787169791582,"version":"build-2736575974"},"reference-count":26,"publisher":"The Endocrine Society","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[1998,10,1]]},"abstract":"<jats:p>Once-daily sc injection of PTH 1\u201334 can normalize mean serum and urine calcium levels in patients with hypoparathyroidism; however, once-daily PTH has diminishing effects on serum calcium after 12 h, such that serum calcium levels fall below the normal range in some patients. Once-daily PTH also causes a marked increase in bone turnover, with persistent increases in markers of bone formation and resorption. To test the hypothesis that a twice-daily PTH regimen can produce more physiological control than a once-daily regimen, we performed a randomized cross-over trial, lasting 28 weeks, in 17 adult subjects with hypoparathyroidism. Each 14-week study arm was divided into a 2-week inpatient dose-adjustment phase and a 12-week outpatient phase. The PTH dose (given sc once daily at 0900 h or twice daily with one dose at 0900 h and the other at 2100 h) was adjusted to maintain both serum and urine calcium within, or close to, the normal range.<\/jats:p>\n                  <jats:p>During the second half of the day (12\u201324 h), twice-daily PTH increased serum calcium and magnesium levels more effectively than once-daily PTH. In patients with calcium receptor mutations (CaR), once-daily PTH normalized urine calcium, provided that serum calcium was maintained at levels below normal range. However, twice-daily PTH treatment produced higher mean serum calcium in patients with CaR with no significant rise in urine calcium excretion, and with no significant differences in either serum or urine calcium levels between CaR and patients with acquired or idiopathic hypoparathyroidism. Thus, treatment with twice-daily PTH is the better regimen for patients with CaR to overcome their tendency to hypercalciuria while producing near-normal levels of serum calcium. The total daily PTH dose was markedly reduced with the twice-daily regimen (twice daily 46 \u00b1 52 vs. once daily 97 \u00b1 60 \u03bcg\/day, P &amp;lt; 0.001). We conclude that a twice-daily PTH regimen provides effective treatment of hypoparathyroidism and reduces the variation in serum calcium levels at a lower total daily PTH dose.<\/jats:p>","DOI":"10.1210\/jcem.83.10.5185","type":"journal-article","created":{"date-parts":[[2014,1,8]],"date-time":"2014-01-08T12:02:45Z","timestamp":1389182565000},"page":"3480-3486","source":"Crossref","is-referenced-by-count":20,"title":["A Randomized, Cross-Over Trial of Once-Daily Versus Twice-Daily Parathyroid Hormone 1\u201334 in Treatment of Hypoparathyroidism"],"prefix":"10.1210","volume":"83","author":[{"given":"Karen K.","family":"Winer","sequence":"first","affiliation":[{"name":"Developmental Endocrinology Branch, National Institutes of Health, Bethesda, Maryland 20892-1862"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack A.","family":"Yanovski","sequence":"additional","affiliation":[{"name":"Developmental Endocrinology Branch, National Institutes of Health, Bethesda, Maryland 20892-1862"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Babak","family":"Sarani","sequence":"additional","affiliation":[{"name":"Developmental Endocrinology Branch, National Institutes of Health, Bethesda, Maryland 20892-1862"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gordon B.","family":"Cutler Jr.","sequence":"additional","affiliation":[{"name":"Developmental Endocrinology Branch, National Institutes of Health, Bethesda, Maryland 20892-1862"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","reference":[{"key":"2020071618250423300_R1","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1542\/peds.72.2.225","article-title":"Hypercalcemia in children with disorders of calcium and phosphate metabolism during long-term treatment with 1,25 dihydroxyvitamin-D3.","volume":"72","author":"Chan","year":"1983","journal-title":"Pediatrics"},{"key":"2020071618250423300_R2","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/S0022-3476(85)80668-5","article-title":"Calcium and phosphate metabolism in children with idiopathic hypoparathyroidism or pseudohypoparathyroidism: effects of 1,25-dihydoxyvitamin D3.","volume":"106","author":"Chan","year":"1985","journal-title":"J Pediatr"},{"key":"2020071618250423300_R3","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/S0140-6736(78)92702-2","article-title":"Deterioration of renal function during the treatment of chronic renal failure with 1,25 dihydroxycholecalciferol.","volume":"2","author":"Christiansen","year":"1978","journal-title":"Lancet"},{"key":"2020071618250423300_R4","first-page":"81","article-title":"High-dose vitamin D therapy: indications, benefits and hazards.","volume":"30","year":"1989","journal-title":"Int J Vitam Nutr Res Suppl"},{"key":"2020071618250423300_R5","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1038\/ki.1987.272","article-title":"Calcium-regulating hormones and the kidney.","volume":"32","year":"1987","journal-title":"Kidney Int"},{"key":"2020071618250423300_R6","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1210\/jcem-55-4-727","article-title":"1,25 Dihydroxyvitamin D-treated hypoparathyroidism: 35 patient years in 10 children.","volume":"55","author":"Markowitz","year":"1982","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071618250423300_R7","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1001\/archpedi.1986.02140160057032","article-title":"Hypercalciuria associated with long-term administration of calcitriol (1, 25-dihydroxyvitamin D).","volume":"140","author":"Santos","year":"1986","journal-title":"Am J Dis Child"},{"key":"2020071618250423300_R8","first-page":"273","article-title":"Nephrocalcinosis in children and adolescents: sonographic evaluation during long-term treatment with 1,25-dihydrocholecalciferol.","volume":"89","author":"Weber","year":"1988","journal-title":"Child Nephrol Urol"},{"key":"2020071618250423300_R9","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1159\/000182285","article-title":"Calcinosis and metastatic calcification due to vitamin D intoxication.","volume":"37","author":"Allen","year":"1992","journal-title":"Horm Res"},{"key":"2020071618250423300_R10","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1210\/jcem-18-3-246","article-title":"Hypocalcemic hypercalciuria during vitamin D and dihydrotachysterol therapy of hypoparathyroidism.","volume":"18","author":"Litvak","year":"1958","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071618250423300_R11","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1172\/JCI110372","article-title":"Short-term effects of synthetic human parathyroid hormone 1\u201334 administration on bone mineral metabolism in osteoporotic patients.","volume":"68","author":"Slovik","year":"1981","journal-title":"J Clin Invest"},{"key":"2020071618250423300_R12","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1002\/jbmr.5650010411","article-title":"Restoration of spinal bone in osteoporotic men by treatment with parathyroid hormone 1\u201334 and 1,25 dihydroxyvitamin D.","volume":"1","author":"Slovik","year":"1986","journal-title":"J Bone Miner Res"},{"key":"2020071618250423300_R13","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1056\/NEJM199412153312404","article-title":"Parathyroid hormone for the prevention of bone loss induced by estrogen deficiency.","volume":"331","author":"Finkelstein","year":"1994","journal-title":"N Engl J Med"},{"key":"2020071618250423300_R14","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1001\/jama.1996.03540080053029","article-title":"Synthetic human parathyroid hormone 1\u201334 vs calcitriol and calcium in the treatment of hypoparathyroidism: results of a randomized crossover trial.","volume":"276","author":"Winer","year":"1996","journal-title":"JAMA"},{"key":"2020071618250423300_R15","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1203\/00006450-199710000-00004","article-title":"A calcium-sensing receptor mutation causes hypoparathyroidism by increasing receptor sensitivity to calcium and maximal signal transduction.","volume":"42","author":"Mancilla","year":"1997","journal-title":"Pediatr Res"},{"key":"2020071618250423300_R16","first-page":"2710","article-title":"Functional characterization of calcium sensing mutations causing sporadic hypoparathyroidism.","volume":"82","author":"DeLuca","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071618250423300_R17","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1093\/clinchem\/33.8.1364","article-title":"Highly sensitive two site immunoradiometric assay of parathyrin and its clinical utility in evaluating patients with hypercalcemia.","volume":"33","author":"Nussbaum","year":"1988","journal-title":"Clin Chem"},{"key":"2020071618250423300_R18","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1210\/jcem-58-1-91","article-title":"A microassay for 1,25 dihydroxy vitamin D not requiring high pressure liquid chromatography: applications in clinical studies.","volume":"58","author":"Reinhardt","year":"1984","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071618250423300_R19","first-page":"517","article-title":"Osteocalcin: isolation, characterization, and detection.","volume":"107","author":"Gundberg","year":"1984","journal-title":"Methods Enzymol"},{"key":"2020071618250423300_R20","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/0169-6009(91)90143-N","article-title":"Urinary excretion of pyridinium crosslinks: a new marker of bone resorption in metabolic bone disease.","volume":"8","author":"Uebelhart","year":"1990","journal-title":"Bone Mineral"},{"key":"2020071618250423300_R21","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1210\/edrv-17-4-289","article-title":"The calcium sensing receptor: a window into the physiology and pathophysiology of mineral ion metabolism.","volume":"17","author":"Chattopadhyay, Mithal","year":"1996","journal-title":"Endocr Rev"},{"key":"2020071618250423300_R22","first-page":"1535","article-title":"Subcutaneous administration of amino-terminal fragment of human parathyroid hormone (1\u201334): kinetics and biochemical response in estrogenized osteoporotic patients.","volume":"77","author":"Linsay","year":"1993","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071618250423300_R23","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1042\/cs0850223","article-title":"Modulation of the anabolic effect of synthetic human parathyroid hormone fragment 1\u201334 in the bone of growing rats by variations in the dosage regimen.","volume":"85","year":"1993","journal-title":"Clin Sci"},{"key":"2020071618250423300_R24","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1210\/endo-110-2-506","article-title":"Parathyroid hormone stimulates the apposition rate independent of its resorptive action: differential effects of intermittent and continuous administration.","volume":"110","author":"Tam","year":"1982","journal-title":"Endocrinology"},{"key":"2020071618250423300_R25","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1002\/jbmr.5650070110","article-title":"Effects of Continuous and Intermittent Administration and Inhibition and resorption on the anabolic response of bone to parathyroid hormone.","volume":"7","author":"Hock","year":"1992","journal-title":"J Bone Miner Res"},{"key":"2020071618250423300_R26","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/BF02553701","volume":"37","author":"Imanaka","journal-title":"Calcif Tiss Int"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/83\/10\/3480\/9230191\/jcem3480.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/83\/10\/3480\/9230191\/jcem3480.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,21]],"date-time":"2022-03-21T19:47:31Z","timestamp":1647892051000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/83\/10\/3480\/2865424"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1998,10,1]]},"references-count":26,"journal-issue":{"issue":"10","published-print":{"date-parts":[[1998,10,1]]}},"URL":"https:\/\/doi.org\/10.1210\/jcem.83.10.5185","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published":{"date-parts":[[1998,10,1]]}}}